MediciNova, Inc. MNOV · Stock Open MediciNova, Inc. in new tab
MediciNova, Inc. Analysis (MNOV)
Is MediciNova, Inc. a good investment? MediciNova, Inc. (MNOV) is currently trading at 3.30 USD. Market analysts have a consensus price target of 8.25 USD. This suggests a potential upside from current levels.
Earnings Schedule: MediciNova, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.52.
Investor FAQ
Does MediciNova, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is MediciNova, Inc.?
MediciNova, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -0.21.
Company Profile
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Community Discussion